Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.
Biomerica reports developments in diagnostic-guided therapies and medical diagnostic products used in point-of-care, home, physician-office and clinical laboratory settings. The company focuses on gastrointestinal and inflammatory diseases, with recurring updates around inFoods® IBS, a finger-stick blood test used to identify individual food triggers for IBS dietary guidance, and Hp Detect™/hp+detect™, an H. pylori stool antigen diagnostic.
Biomerica news also covers commercialization and regulatory activity for products such as EZ Detect™, an at-home colorectal disease screening test, along with international distribution, laboratory partnerships, reimbursement and coding updates, clinical data presentations, fiscal results and the company’s CDMO services activity.
Biomerica (Nasdaq: BMRA) has received approval from the Saudi Food and Drug Authority (SFDA) for its Fortel® Prostate (PSA) Screening Test. This at-home test allows men to detect early signs of prostate cancer in just 10 minutes using a finger-prick blood sample. The test has shown impressive performance, with studies reporting up to 100% sensitivity and 97.5% accuracy compared to laboratory methods.
This approval marks Biomerica's strategic expansion into the Middle East, where prostate cancer is a growing concern. The company has already shipped its first order to Saudi Arabia and aims to replicate the success of its EZ Detect Colon Disease test, which has secured insurance reimbursement in Dubai.
Prostate cancer is the second most common cancer in men globally, with 1.4 million new cases diagnosed in 2020. Biomerica's Fortel® PSA test aims to address the need for early detection in the region, where comprehensive studies on prostate cancer are still lacking.
Biomerica reported fiscal 2024 year-end results with a 1% increase in total revenue to $5.4 million. Core revenue, excluding COVID tests, grew by 5%. The company improved its gross margin to 11% from 8% and reduced its net loss by 15% to $6.0 million. Biomerica implemented a cost-savings plan expected to reduce expenses by $1.0 to $1.4 million in the coming year.
Key achievements include FDA 510(k) clearance for the Hp Detect™ Stool Antigen ELISA test, advancement of the inFoods® IBS diagnostic test with a new patient self-collection system, and an exclusive distribution agreement in the UAE for EZ Detect™ and Aware® products. The company is focusing on three strategic growth areas: expanding at-home tests in the MENA region, capitalizing on H. pylori antigen sales in the U.S., and expanding inFoods® IBS opportunities.
Biomerica (Nasdaq: BMRA) has launched an at-home sample collection system for its inFoods® IBS diagnostic test, enhancing patient convenience and expanding access to millions of IBS sufferers. Using a simple finger-stick method, patients can now self-collect blood samples at home, eliminating the need for healthcare facility visits. This innovation allows the inFoods® IBS product to be offered nationwide through telehealth and online medical providers, potentially increasing product revenues. With IBS affecting one in twenty Americans and contributing to $10 billion in medical costs annually, Biomerica's new system aims to provide cost-effective, non-pharmaceutical solutions by identifying dietary triggers for IBS symptoms.
Biomerica, Inc. (Nasdaq: BMRA) has announced the pilot launch of its inFoods® IBS product with a 1,100-member physician group starting in June 2024. This innovative technology aims to identify dietary triggers for IBS symptoms, providing relief for the majority of patients. IBS affects 10-15% of the global population, with associated direct medical costs of $21 billion annually. The positive clinical data of inFoods IBS will be presented at the 2024 Digestive Disease Week Conference.
Biomerica Inc. (Nasdaq: BMRA) announced an exclusive distribution agreement with a UAE healthcare conglomerate for their at-home screening products, EZ Detect™ for colorectal cancer and Aware® for breast exams. The Dubai Healthcare Authority approved insurance reimbursement for EZ Detect™, enhancing accessibility. The partnership aims to integrate these tests into national health protocols, with potential for introduction of more Biomerica products in the UAE. EZ Detect™ simplifies colorectal screening by detecting occult blood in stool, revolutionizing at-home testing. Aware® increases tactile sensitivity during breast self-exams, important for early breast cancer detection. The collaboration signifies a step towards proactive health management in the Middle East, with a focus on reducing the burden of cancer through early detection.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.